Skip to product information

Harvard 21st Biennial Course in Urologic Oncology 2022

Harvard 21st Biennial Course in Urologic Oncology 2022

Regular price $60.00 USD
Regular price $60.00 USD Sale price
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out
Harvard 21st Biennial Course in Urologic Oncology 2022

Harvard 21st Biennial Course in Urologic Oncology 2022

Regular price $60.00
Regular price $60.00 Sale price
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out
  • Share positive thoughts and feedback from your customer.

    Author
  • Share positive thoughts and feedback from your customer.

    Author
  • Share positive thoughts and feedback from your customer.

    Author
    View full details

    Harvard 21st Biennial Course in Urologic Oncology 2022


    Biennial Course in Urologic Oncology

    2022 Course Overview

    Who Should Attend

    • Primary Care Physicians
    • Specialty Physicians
    • Nurses
    • Nurse Practitioners
    • Pharmacists
    • Physician Assistants
    • Psychologists

    Learning Objectives


    Upon completion of this activity, participants will be able to:
    • Demonstrate the optimal management of oligometastatic prostate, bladder, renal cancer
    • Explain the role of immunotherapy in the management of bladder, prostate and renal cancer
    • Determine how to incorporate genomic classifiers, multiple parametric MRI, and clinical parameters into selecting optimal patients with prostate cancer for active surveillance or other definitive management approaches
    • Apply Level 1 evidence on the use of novel treatment paradigms and updated surveillance options for patients with prostate, renal, bladder, or testicular cancer
    • Apply novel minimally invasive treatments for GU malignancies including prostate, bladder and kidney cancer
    • Use multiparametric MRI, fusion biopsy and novel markers in men at risk for prostate cancer
    • Biennial Course in Urologic Oncology
    THURSDAY, OCTOBER 13, 2022
    7:15 – 8:00 AM


    Registration

    8:00 – 8:05 AM


    Welcome
    Anthony D’Amico

    8:05 – 8:20 AM


    Epidemiology and Genetics
    Lorelei Mucci

    8:20 – 8:35 AM


    Screening in 2022: Role of PSA and Novel Biomakers
    Adam Kibel

    8:35 – 8:50 AM


    Advanced in Multiparametric MRI for Diagnosis and Staging
    Clare Tempany

    8:50 – 9:05 AM


    Interpreting Prostrate Biopsy Reports
    Michelle Hirsch

    9:05 – 9:30 AM


    Expert Panel: Screening and Diagnosis
    Moderator: Anthony D’Amico
    Speakers: Michelle Hirsch, Adam Kibel, Lorelei Mucci and Clare Tempany

    9:30 – 10:00 AM


    Break

    10:00 – 10:15 AM


    Focal Ablation and Active Surveillance in Intermediate Risk Disease
    Alexander Cole

    10:15 – 10:30 AM


    Radical Prostatectomy in Intermediate Risk Disease
    Quoc-Dien Trin

    10:30 AM – 10:45 AM


    Hypofractionation and ADT use in Intermediate Risk Prostate Cancer
    Neil Martin

    10:45 – 11:00 AM


    MRI Guided Radiation therapy
    Jonathan Leeman

    11:00 – 11:15 AM


    Optimizing Systemic Therapy in the Management of Intermediate and High-Risk Prostate Cancer
    Anthony D’Amico

    11:15 – 11:30 AM


    Novel Approaches in the Preoperative Setting for the High-Risk Patient
    Mary-Ellen Taplin

    11:30 – 11:45 AM


    Biomarker Based Clinical Trials and Prostate Cancer
    Martin Gleave

    11:45 AM – 12:15 PM


    Expert Panel: Patient Selection
    Moderator: Anthony D’Amico
    Speakers: Alexander Cole, Martin Gleave, Jonathan Leeman, Neil Martin, Mary-Ellen Taplin, Quoc-Dien Trinh

    12:15 – 1:00 PM


    Lunch

    1:00 – 1:15 PM


    PET Imaging in the PSA Recurrent Setting-Diagnostics
    Heather Jacene

    1:15 – 1:30 PM


    Treatment of Oligo Metastatic Disease, Integration of Surgery
    Speaker: Martin Gleave

    1:30 – 1:45 PM


    Treatment of Oligo Metastatic Disease, Integration of Radiation
    Paul Nguyen

    1:45 – 2:00 PM


    Precision Medicine in Prostate Cancer
    Himisha Beltran

    2:00 – 2:30 PM


    Expert Panel: Updates in Diagnostics and Special Populations
    Moderator: Adam Kibel
    Speakers: Himisha Beltran, Martin Gleave, Heather Jacene and Paul Nguyen

    2:30 – 2:45 PM


    Break

    2:45 – 3:00 PM


    Adjuvant versus Salvage Radiation
    Anthony D’Amico

    3:00 – 3:15 PM


    Management of the Rising PSA in the Patient with M0 Castrate Sensitive Prostate Cancer
    Charles Ryan

    3:15 – 3:30 PM


    Management of Advanced Prostate Cancer in the Elderly
    Alicia Morgans

    3:30 – 3:45 PM


    Survivorship and Side effects of ADT
    Phil Saylor

    3:45 – 4:00 PM


    Management of Side Effects of Radical Prostatectomy in the Denovo and Recurrent Settings
    Peter Chang

    4:00 – 4:15 PM


    Management of Side Effects of Radiation Therapy in the Denovo and Recurrent Settings
    Daniel Schmidt

    4:15 – 4:30 PM


    Management of the Side Effects of Non-ADT Systemic Treatment for Prostate Cancer
    Mark Pomerantz

    4:30 – 5:00 PM


    Expert Panel: Management of Treatment Related Toxicity and Recurrent Disease
    Moderator: Adam Kibel
    Speakers: Peter Chang, Anthony D’Amico, Alicia Morgans, Mark Pomerantz, Charles Ryan, Phil Saylor and Daniel Schmidt

    FRIDAY, OCTOBER 14, 2022
    8:00 AM – 8:15 AM


    Management of the Rising PSA in the Patient with M0 Castrate Resistant Prostate Cancer
    Atish Choudhury

    8:15 – 8:30 AM


    Personalizing Treatment Selection in Metastatic, Hormone-sensitive Prostate Cancer
    Christopher Sweeney

    8:30 – 8:45 AM


    Immunotherapy for Prostate Cancer
    Xiao Wei

    8:45 – 9:00 AM


    Novel Androgen Receptor Targeted therapy of Castrate Resistant M1 PC

    9:00 – 9:15 AM


    PET Imaging in the PSA Recurrent Setting – Therapeutics
    Praful Ravi

    9:15 – 9:45 AM


    Expert Panel: Management of Metastatic Prostate Cancer
    Moderator: Glenn Bubley
    Speakers: Atish Choudhury, Praful Ravi, Charles Ryan, Christopher Sweeney, and Xiao Wei

    9:45 – 10:15 AM


    Break

    10:15 – 10:45 AM


    Special Lecture, Kidney Development and Wilms Tumor: Prospects for Regeneration
    George Daley

    10:45 – 11:00 AM


    Role of Biomarkers in Diagnosis and Follow-up
    Adam Feldman

    11:00 – 11:15 AM


    Management of Superficial Bladder Cancer
    Angela Smith

    11:15 – 11:30 AM


    Genomics and its Role in the Management of Bladder Cancer
    Joaquim Bellmunt

    11:30 – 11:45 AM


    Management of Upper Tract Disease
    Matthew Mossanen

    11:45 AM – 12:00 PM


    Urinary Diversion after Cystectomy, Choices and Outcomes
    Andrew Wagner

    12:00 – 12:15 PM


    Lymph Node Dissection and Approaches to Radical Cystectomy
    Mark Preston

    12:15 – 1:00 PM


    Lunch

    1:00 – 2:00 PM


    Judah Folkman Lecture: Emerging Strategies in the Fight Against Covid-19
    Lindsey Baden

    2:00 – 2:15 PM


    Genomic Predictors of Response to Chemotherapy
    Kent Mouw

    2:15 – 2:30 PM


    Personalizing Bladder Cancer Treatment in Variant Histology
    Angela Smith

    2:30 – 2:45 PM


    Neoadjuvant and Adjuvant Chemotherapy
    Richard Lee

    2:45 – 3:00 PM


    Bladder Sparing Approaches
    Jason Efstathiou

    3:00 – 3:15 PM


    Chemo and Immunotherapy for Advanced Urothelial Cancer
    Joaquim Bellmunt

    3:15 – 3:45 PM


    Expert Panel: Bladder Cancer
    Moderator: Adam Kibel
    Speakers: Joaquim Bellmunt, Jason Efstathiou, Adam Feldman, Richard Lee,  Kent Mouw, Matthew Mossanen, Mark Preston, Angela Smith and Andrew Wagner

    3:45 PM – 4:00 PM


    Break

    4:00 – 4:15 PM


    Management of Seminoma
    Alok Tewari

    4:15 – 4:30 PM


    Management of Stage I non-seminoma
    Timothy Clinton

    4:30 – 4:45 PM


    Updates in Radiation Therapy in Testis Cancer
    Sophia Kamran

    4:45 – 5:00 PM


    Management of Advanced Disease-Chemotherapy
    Christopher Sweeney

    5:00 – 5:15 PM


    Emerging Role of Genomics in Testis Cancer
    Eliezer Van Allen

    5:15 – 5:45 PM


    Expert Panel: Testis Cancer
    Moderator: Jerome Richie
    Speakers: Timothy Clinton, Sophia Kamran, Christopher Sweeney, Alok Tewari and Eliezer Van Allen

    SATURDAY, OCTOBER 15, 2022
    8:00 – 8:15 AM


    Tackling Tumor Metabolism in Renal Cell Carcinoma
    Kimryn Rathmell

    8:15 – 8:30 AM


    Updated in the Pathology Classification of Renal Cell Cancer
    Michelle Hirsch

    8:30 – 8:45 AM


    Role of Observation and Ablation for Small Renal Mass
    Aria Olumi

    8:45 – 9:00 AM


    Radical or Partial Nephrectomy: Techniques and Innovations
    Steven Chang

    9:00 – 9:15 AM


    Managing the Primary when Metastatic and Metastatectomy
    Keyan Salari

    9:15 – 9:30 AM


    Adjuvant Strategies in RCC
    Toni Choueiri

    9:30 – 10:00 AM


    Break

    10:00 – 10:15 AM


    Advanced Disease: First Line Options
    Vincent Xu

    10:15 – 10:30 AM


    Advanced Disease: Post IO Setting
    David McDermott

    10:30 – 10:45 AM


    Non Clear Cell RCC
    Bradley McGregor

    10:45 – 11:00 AM


    Novel Targets Beyond Targeted Agents and IO Drugs
    Xin Gao

    11:00 AM – 12:00 PM


    Expert Panel: Renal Cell Carcinoma
    Moderator: Tonu Choueiri
    Speakers: Steven Chang, Xin Gao, Michelle Hirsch, David McDermott, Bradley McGregor, Aria Olumi, Kimryn Rathmell, Keyan Salari and Vincent Xu


    Biennial Course in Urologic Oncology